Lawrence M. Blatt - 09 Mar 2026 Form 4 Insider Report for Aligos Therapeutics, Inc. (ALGS)

Role
President and CEO, Director
Signature
/s/ Lesley Ann Calhoun, as attorney-in fact for Lawrence M. Blatt
Issuer symbol
ALGS
Transactions as of
09 Mar 2026
Net transactions value
$0
Form type
4
Filing time
11 Mar 2026, 16:13:06 UTC
Previous filing
18 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
BLATT LAWRENCE President and CEO, Director C/O ALIGOS THERAPEUTICS, INC., 1 CORPORATE DRIVE, 2ND FLOOR, SOUTH SAN FRANCISCO /s/ Lesley Ann Calhoun, as attorney-in fact for Lawrence M. Blatt 11 Mar 2026 0001242110

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALGS Stock Option (Right to Buy) Award +105,840 $0.000000* 105,840 09 Mar 2026 Common Stock 105,840 $7.03 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 9, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.